|
| Press Releases |
|
 |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
| Wednesday, April 19, 2017 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis |
| Eisai Co., Ltd. has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. more info >> |
|
| Tuesday, April 11, 2017 |
|
|
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series |
| Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. more info >> |
|
| Wednesday, April 5, 2017 |
|
|
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that they have entered into a license agreement for the commercialization of safinamide for the treatment of Parkinson's disease in Japan and Asia. Safinamide is currently under clinical development by Meiji in Japan. more info >> |
|
|
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting |
| Eisai Co., Ltd. announced today that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate and an anti-mouse PD-1 antibody, at the AACR 108th Annual Meeting. more info >> |
|
| Tuesday, April 4, 2017 |
|
|
Eisai to Launch Smell Identification Test UPSIT Series in Japan |
| Eisai Co., Ltd. has announced that the smell identification test "UPSIT Series" will be launched today for sale to health insurance pharmacies and local governments in Japan. more info >> |
|
| Wednesday, March 29, 2017 |
|
|
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan |
| Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat in patients with early Alzheimer's disease (AD). more info >> |
|
|
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house developed anticancer agent Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) compared to everolimus alone in its assessment for insurance reimbursement. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Baguio Wins Two Contracts for Smart Food Waste Recycling Machines and Smart Balances from EPD
Jan 20, 2025 21:20 HKT/SGT
|
|
|
碧瑶赢得环保署智能厨余回收机及智能磅两份合约
Jan 20, 2025 21:12 HKT/SGT
|
|
|
碧瑤贏得環保署智能廚餘回收機及智能磅兩份合約
Jan 20, 2025 20:41 HKT/SGT
|
|
|
DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
|
|
|
Transforming Philippine Healthcare: The 2025 Philippine Hospital & Healthcare Digitalization Summit
Jan 20, 2025 16:59 HKT/SGT
|
|
|
Q2 Metals Announces Details of its Expansion Drill Program for the Cisco Lithium Project in Eeyou Istchee James Bay, Quebec
Jan 20, 2025 16:05 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 20, 2025 15:30 HKT/SGT
|
|
|
三菱重工、人事異動を発表
Jan 20, 2025 15:30: JST
|
|
|
Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States
Jan 20, 2025 15:07 JST
|
|
|
三菱造船とTPFC、タブレット端末を利用したポータブル運航支援システム「ナビン」のリース販売を開始
Jan 20, 2025 14:00: JST
|
|
|
Suzuki's First BEV "e VITARA" Adopts eAxle
Jan 20, 2025 13:58 JST
|
|
|
Honda、「FREED e:HEV｣を一部改良
Jan 20, 2025 11:20: JST
|
|
|
Green Rain Solar Inc.（現代公司 The Now Corporation (OTC:NWPN) 的子公司）宣布推出帶有整合灌溉和備用電力系統的自給式太陽能溫室
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Hypertec Cloud 與 Potentia 合作推動可持續 AI 雲端擴展，在北美新增 480MW 的平衡容量
Jan 20, 2025 11:00 HKT/SGT
|
|
|
Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025
Jan 20, 2025 11:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
